L

Lipella Pharmaceuticals Inc
NASDAQ:LIPO

Watchlist Manager
Lipella Pharmaceuticals Inc
NASDAQ:LIPO
Watchlist
Price: 0.174 USD 18.37%
Market Cap: $803.9k

Operating Margin

-998.4%
Current
Improving
by 59.7%
vs 3-y average of -1 058.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-998.4%
=
Operating Income
$-5.2m
/
Revenue
$519.9k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-998.4%
=
Operating Income
$-5.2m
/
Revenue
$519.9k

Peer Comparison

Country Company Market Cap Operating
Margin
US
Lipella Pharmaceuticals Inc
NASDAQ:LIPO
803.9k USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
390.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.8B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 93% of companies in the United States of America
Percentile
7th
Based on 14 112 companies
7th percentile
-998.4%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Lipella Pharmaceuticals Inc
Glance View

Market Cap
803.9k USD
Industry
Biotechnology

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 4 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10 and LP-310. LP-10 is its proprietary formulation of tacrolimus and is optimized for local delivery to the urinary bladder. LP-310, another proprietary formulation of tacrolimus, is optimized for delivery to the oral mucosa (the tissue lining the walls inside the mouth) and tongue surface. The company is developing LP-310 for the treatment of oral lichen planus (OLP), a chronic inflammatory condition affecting the mucous membranes inside the mouth. The company has developed a proprietary technology, referred to as its Platform, which is optimized for local hydrophobic drug delivery to body cavities having endothelial surfaces. Its Platform includes proprietary drug delivery technologies optimized for use with epithelial tissues.

LIPO Intrinsic Value
0.791 USD
Undervaluation 78%
Intrinsic Value
Price
L
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-998.4%
=
Operating Income
$-5.2m
/
Revenue
$519.9k
What is Lipella Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for Lipella Pharmaceuticals Inc is -998.4%, which is above its 3-year median of -1 058.1%.

How has Operating Margin changed over time?

Over the last 2 years, Lipella Pharmaceuticals Inc’s Operating Margin has increased from -1 405.9% to -998.4%. During this period, it reached a low of -1 405.9% on Dec 1, 2022 and a high of -839.2% on Jun 30, 2024.

Back to Top